fluoxetine has been researched along with fluvoxamine in 295 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 12 (4.07) | 18.7374 |
1990's | 130 (44.07) | 18.2507 |
2000's | 90 (30.51) | 29.6817 |
2010's | 45 (15.25) | 24.3611 |
2020's | 18 (6.10) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J | 1 |
Dansette, PM; Fontana, E; Poli, SM | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Qin, W; Tian, S; Wold, EA; Xu, Q; Ye, N; Zhen, XC; Zhou, J | 1 |
Bojarski, AJ; Bugno, R; Duszyńska, B; Hogendorf, A; Hogendorf, AS; Kurczab, R; Lenda, T; Pietruś, W; Satała, G; Staroń, J; Wantuch, A; Warszycki, D | 1 |
Karsch, V; Starke, K; Szabo, B | 1 |
Anthony, DT; Fallon, BA; Hollander, E; Klein, DF; Liebowitz, MR; Schneier, FR; Stein, DJ | 1 |
Crewe, HK; Haddock, RE; Lennard, MS; Tucker, GT; Woods, FR | 1 |
Carrasco, JL; Hollander, E; Liebowitz, MR; Schneier, FR | 1 |
Baumann, P; Bertschy, G; Bizouard, P; Bonin, B; Bouquet, S; Francois, T; Sechter, D; Vandel, S; Volmat, R | 1 |
Bertschy, G; Bizouard, P; Bonin, B; Bouquet, S; Sechter, D; Vandel, B; Vandel, S | 1 |
Goodman, WK; McDougle, CJ; Price, LH | 3 |
Kindler, S; Zohar, J | 1 |
Corrigan, FM | 1 |
Kaspi, N; Sirota, P | 1 |
DeVane, CL | 1 |
Johnson, AM; Tulloch, IF | 1 |
March, JS | 1 |
Kapur, S; Mann, JJ | 1 |
Brockmöller, J; Müller, N; Roots, I | 1 |
George, MS | 1 |
Baldwin, D; Bullock, T; Montgomery, D; Montgomery, S | 1 |
Guimaraes, FS | 1 |
Baldwin, D; Fineberg, N; Montgomery, S | 1 |
Mavissakalian, MR; Tamimi, RR | 1 |
DeCaria, CM; Hollander, E; Klein, DF; Liebowitz, MR; Schneier, FR; Schneier, HA | 1 |
DeCaria, C; Fairbanks, J; Fallon, B; Hollander, E; Klein, DF; Liebowitz, MR | 1 |
Insel, TR | 1 |
Hoehn-Saric, R; Lipsey, JR; McLeod, DR | 1 |
Baer, L; Buttolph, L; Holland, A; Hyman, S; Jenike, MA; Minichiello, WE; Ricciardi, J; Seymour, R; Summergrad, P | 1 |
Greist, JH; Johnston, H; March, JS | 1 |
Fuller, RW | 1 |
Asberg, M; Eriksson, B; Mårtensson, B; Träskman-Bendz, L; Wägner, A | 1 |
Mendels, J | 1 |
Netter, P | 1 |
Cole, JO; Dessain, E; Katz, DL; O'Neil, P; Schatzberg, AF | 1 |
Durcan, MJ; Eckardt, MJ; Linnoila, M; Lister, RG | 2 |
Harms, HH | 1 |
Bymaster, FP; Reid, LR; Threlkeld, PG; Wong, DT | 1 |
Maj, J; Rogóz, Z; Skuza, G; Sowińska, H | 1 |
Baumann, P; Rochat, B | 1 |
Anelli, M; Caccia, S; Codegoni, AM; Fracasso, C; Garattini, S | 1 |
Finley, PR | 1 |
Hyttel, J; Sánchez, C | 1 |
Greist, JH; Jefferson, JW; Katzelnick, DJ; Kobak, KA; Serlin, RC | 1 |
Jordan, S; Kramer, GL; Moeller, M; Petty, F; Zukas, PK | 1 |
Conte, G; Guarneri, L; Sacchetti, E | 1 |
Carroll, BJ | 1 |
Bianchi, M; Panerai, AE; Sacerdote, P | 1 |
Dominguez, RA; Mestre, SM | 1 |
Edwards, JG; Inman, WH; Pearce, GL; Wilton, L | 1 |
Mattes, JA | 1 |
Brøsen, K | 2 |
Jackson, CW; Lydiard, RB; Morton, WA | 1 |
Fux, M; Taub, M; Zohar, J | 1 |
Glancy, GD | 1 |
Avenoso, A; Caputi, AP; Fazio, A; Pisani, F; Pollicino, AM; Spina, E | 1 |
Joffe, RT; Schuller, DR | 1 |
Bellodi, L; Mundo, E; Ronchi, P | 1 |
Alhaider, AA; Mustafa, AA | 1 |
de Koning, GH; Ottervanger, JP; Stricker, BH; van den Bemt, PM | 1 |
Eagles, JM; Parkin, JR | 1 |
Rasker, MC | 1 |
LaBranche, S | 1 |
Brieaddy, L; Cooper, B; Ferris, RM; Hollingsworth, E; Mehta, N; Rigdon, G; Soroko, F; Wang, C; Wastila, W | 1 |
Joffe, RT; Levitt, AJ; Sokolov, ST; Young, LT | 1 |
Newhouse, PA | 1 |
Aizenberg, D; Weizman, A; Zemishlany, Z | 1 |
Baumann, P; Bertschy, G; Bizouard, P; Bonin, B; Bouquet, S; Francois, T; Sechter, D; Vandel, S | 1 |
Knowles, SR; Liu, BA; Mittmann, N; Shear, NH | 1 |
Artigas, F; Bel, N | 1 |
Harvey, AT; Preskorn, SH | 2 |
Baumann, P; Eap, CB; Gaillard, N; Powell, K | 1 |
Brøsen, K; Gram, LF; Jeppesen, U; Loft, S; Poulsen, HE; Vistisen, K | 1 |
Carpenter, LL; Epperson, CN; McDougle, CJ; Price, LH | 1 |
Baumann, P; Bertschy, G; Eap, CB; Powell, K | 2 |
Bradford, D; Coccaro, E; Fabre, L; Holland, P; Perse, T; Rapaport, M; Sheline, Y | 1 |
Catalano, M; Lucca, A; Lucini, V; Smeraldi, E | 1 |
Leo, RJ | 1 |
Harnett-Sheehan, K; Sheehan, DV | 1 |
Iancu, I; Kindler, S; Sasson, Y; Weizman, A; Zohar, J | 1 |
de Vet, HC; Hartmans, M; Honig, A; Menting, JE; Rozendaal, N; van Praag, HM; Verhey, FR | 1 |
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM | 1 |
Barzega, G; Bellino, S; Bogetto, F; Maina, G; Ravizza, L | 1 |
Preskorn, SH | 1 |
Brown, J; Del Boca, FK; Korner, PF; Kranzler, HR | 1 |
Baumann, P; Eap, CB | 1 |
MacKay, AV; Price, JS; Waller, PC; Wood, SM | 1 |
Bradford, JM; Curry, S; Greenberg, DM; O'Rourke, A | 1 |
Bardgett, ME; Csernansky, JG; Sheline, Y | 1 |
Meier, E; Sánchez, C | 1 |
Dager, SR; Hayes, CE; Layton, ME; Strauss, WL | 1 |
Earley, B; Faherty, CJ; Leonard, BE | 1 |
Dannon, PN; Iancu, I; Kindler, S; Sasson, Y; Zohar, J | 1 |
Black, KJ; Sheline, YI | 1 |
Alamo, C; Carvajal, A; Hervás, J; Velasco, A | 1 |
Bourin, M; Redrobe, JP | 2 |
Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD | 1 |
Ahern, D; Ball, SE; Kao, J; Scatina, J | 1 |
Lopukhov, IG | 1 |
Klenk-Majewska, B; Lupina, T; Ossowska, G; Pietrasiewicz, T; Zebrowska-Lupina, I | 1 |
den Boer, JA | 1 |
Mitchell, S; Tracy, KA; Zajecka, J | 1 |
Anand, A; Barr, LC; Goodman, WK; McDougle, CJ; Price, LH | 1 |
Bousoño, M; Calcedo, A; Carrasco, JL; Ciudad, J; Daniel, E; De la Gandara, J; Derecho, J; Franco, M; Gomez, MJ; Izquierdo, JA; Ledesma, A; Llorca, G; Macias, JA; Martin, T; Montejo-González, AL; Perez, V; Sanchez, JM; Sanchez, S; Vicens, E | 1 |
Richelson, E | 2 |
Bisserbe, JC; Flament, MF | 1 |
Gorman, JM | 1 |
Costa, E; Davis, JM; Guidotti, A; Rasmusson, A; Sheline, Y; Uzunov, DP; Uzunova, V | 1 |
Fundaró, A | 1 |
Berthou, F; Dréano, Y; Iribarne, C; Picart, D | 1 |
Mazo, GE; Razorenov, GI; Razorenova, TS; Vovin, RIa | 1 |
Dirksen, R; Van Luijtelaar, EL; Van Rijn, CM | 1 |
Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P | 1 |
Hengeveld, MW; Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
Barbey, JT; Roose, SP | 1 |
Cheriex, EC; Honig, A; Lousberg, R; Strik, JJ; Van Praag, HM | 1 |
Berendsen, HH; Bouwknecht, JA; Broekkamp, CL; Gommans, J; Hijzen, TH; Maes, RA; Olivier, B | 1 |
Stahl, SM | 1 |
Goudemand, M; Rousseaux, M; Thomas, P | 1 |
Coccaro, EF; Hauger, RL; Kavoussi, RJ | 1 |
Alvarez, E; Artigas, F; Pérez, V; Puigdemont, D; Soler, J | 1 |
Alfaro, CL; Ereshefsky, L; Lam, YW; Simpson, J | 1 |
Meyers, BS | 1 |
De Vry, J; Maurel, S; Schreiber, R | 1 |
Deslandes, A; Magariños, AM; McEwen, BS | 1 |
Epperson, CN; Fasula, D; McDougle, CJ; Price, LH; Wasylink, S | 1 |
Daniel, WA; Haduch, A; Syrek, M; Wójcikowski, J | 2 |
Baer, L; Jenike, MA; Manzo, PA; Mataix-Cols, D; Rauch, SL | 1 |
Carleborg, L; Hägg, S; Ohman, R; Spigset, O | 1 |
Sheehan, DV | 1 |
Gorfinkle, KS; Liebowitz, MR; Simpson, HB | 1 |
Inoue, K; Sugimoto, Y; Yamada, J | 1 |
Churchill, E; Davidson, JR; Meltzer-Brody, S | 1 |
Härtter, S; Hiemke, C | 1 |
Borgeat, F; Freeston, MH; Todorov, C | 1 |
Aguas Nuevo, E; Berzas Nevado, JJ; Contento Salcedo, AM; Villaseñor Llerena, MJ | 1 |
Gentilini, G; Lopez-Silva, S; Lucca, A; Soldarini, A | 1 |
Mielech, K; Starczewska, B | 1 |
Baranowska, K; Puzanowska-Tarasiewicz, H; Starczewska, B | 1 |
Baier, D; Kohnen, R; Philipp, M; Tiller, JW | 1 |
Bolo, NR; Hodé, Y; Lainé, E; Macher, JP; Nédélec, JF; Wagner, G | 1 |
Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
Buzinkaiová, T; Polonský, J | 1 |
Norrholm, SD; Ouimet, CC | 1 |
Woods, SW | 1 |
Fitzgerald, F; Glod, CA; Lynch, A | 1 |
Dewa, CS; Goering, P; Hoch, JS | 1 |
Grewal, A; Lam, RW; Lee, SK; Tam, EM; Yatham, LN | 1 |
Baba, J; Fujishiro, J; Imanishi, T; Kosaka, K | 1 |
Apter, A; Kohn, Y; Weizman, A | 1 |
Bergsholm, YK; Bøhler, E; Nordeng, H; Spigset, O | 1 |
Alonso, P; Mataix-Cols, D; Menchon, JM; Pifarre, J; Salgado, P; Torres, L; Vallejo, J | 1 |
Camarero, J; Colado, MI; Esteban, B; Green, AR; Peter, MJ; Sanchez, V | 1 |
Knoke, DM; Naranjo, CA | 1 |
Dratcu, L | 1 |
Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS | 1 |
Cullen, N; Lexell, J; Zafonte, RD | 1 |
Hashimoto, S; Hattori, T; Kawasaki, K; Kitamura, Y; Miki, N; Mochizuki, D; Otsuka, Y; Tsujita, R; Yamada, S | 1 |
Alfaro, CL; Ereshefsky, L; Gaedigk, A; Lam, YW; Simpson, J | 1 |
Caffieri, S; Giusti, P; Imbesi, M; Levorato, L; Manev, H; Manev, R; Miolo, G; Uz, T | 1 |
Abikoff, H; Bergman, RL; Davies, M; Fairbanks, J; Gammon, P; Greenhill, L; Hack, S; Klee, B; Klein, R; Labellarte, M; Lynn, D; March, J; McCracken, J; Pine, DS; Riddle, MA; Ritz, L; Roper, M; Sweeney, M; Vitiello, B; Walkup, J | 1 |
Sugimoto, Y; Yamada, J | 1 |
Entsuah, R; Rudolph, RL; Stahl, SM | 1 |
Anderson, TA; Dobscha, SK; Hauser, P; Hoffman, WF; Snodgrass, LS; Turner, EH; Winterbottom, LM | 1 |
Bubar, MJ; Cunningham, KA; De Deurwaerdère, P; McMahon, LR; Spampinato, U | 1 |
Baba, J; Fujiwara-Sawada, M; Imanishi, T; Yoshida, A | 1 |
Ikeda, K; Kobayashi, T; Washiyama, K | 1 |
Białous, B; Jasińska, A; Starczewska, B | 1 |
Dalery, J; Honig, A | 1 |
Kamei, J; Miyata, S; Morita, K; Saitoh, A; Takeda, H | 1 |
Bocchetta, A; Del Zompo, M; Martinelli, V; Palmas, AM | 1 |
Alfaro, CL; Ereshefsky, L; Lam, YW; Miller, M | 1 |
Broocks, A; Hohagen, F; Kordon, A | 1 |
Anderson, GM; Dodson, AM; Rhoden, KJ | 1 |
Masuda, Y; Shimizu, T | 1 |
Bolo, NR; Hodé, Y; Macher, JP | 1 |
Eichner, SF; Jones, JR; Moore, ML | 1 |
Casciano, R; Chen, J; Geissler, EC; Mallick, R; Panish, JM; Trivedi, MH; Wan, GJ | 1 |
Armbrust, KL; Black, MC; Henry, TB; Kwon, JW | 1 |
Hirano, K; Kagawa, Y; Kimura, R; Maruyama, S; Yamada, S | 1 |
Silver, H | 1 |
Albert, U; Bogetto, F; Maina, G; Salvi, V | 1 |
Atmaca, S; Baktr, G; Cetin, SM; Ersoy, L; Ertürk, S | 1 |
Hashimoto, H; Hirano, K; Kato, Y; Kimura, R; Sugimoto, Y; Uchida, S; Yamada, J; Yamada, S | 1 |
Fontenelle, LF; Mendlowicz, MV; Versiani, M | 1 |
Amireault, P; Dubé, F | 1 |
Sharma, S; Tandon, R; Trivedi, JK | 1 |
Bader, M; Lookingland, K; Murphy, DL; Ni, W; Watts, SW; Wilhelm, CS | 1 |
Cela, R; Garcia-Jares, C; Lamas, JP; Llompart, M; Salgado-Petinal, C | 1 |
Bestari, KJ; Brain, RA; Johnson, DJ; Sanderson, H; Solomon, KR; Wilson, CJ | 1 |
Dinca, O; Paul, M; Spencer, NJ | 1 |
Carrasco, JL; Sandner, C | 1 |
Furumoto, M; Haito, S; Ito, M; Kawai, Y; Miyamoto, K; Terao, J | 1 |
Pick, CG; Schreiber, S | 1 |
Gupta, G; Kumar, VS; Maikhuri, JP; Sharma, VL; Singh, D; Singh, MM; Tiwari, P | 1 |
Anderson, SW; Booker, MB | 1 |
Berger, U; Jensen, E; Kallenborn, R; Samuelsen, PJ; Vasskog, T | 1 |
Brain, RA; Johnson, DJ; Sanderson, H; Solomon, KR; Wilson, CJ | 1 |
Belmaker, RH; Nemets, B; Shapira, B; Trachtenberg, A | 1 |
Bailly, D | 1 |
Baraldi, C; Bassi, T; Bellodi, L; Cavedini, P; Gorini, A; Ubbiali, A; Zorzi, C | 1 |
Bazinet, RP; Chang, L; Ertley, RN; Lee, HJ; Rao, JS; Rapoport, SI | 1 |
Hallifax, D; Houston, JB | 1 |
Brown, HS; Chadwick, A; Houston, JB | 1 |
Benattia, I; Demitrack, M; Entsuah, R; Nemeroff, CB; Sloan, DM; Thase, ME | 1 |
Busto, G; Di Spigno, D; Falcini, R; Salvati, L; Tundo, A | 1 |
Barton, R | 1 |
Olivier, B; Schweitzer, DH; Waldinger, MD; Zwinderman, AH | 1 |
Balayssac, S; Gilard, V; Malet-Martino, M; Martino, R; Trefi, S | 1 |
Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R | 1 |
Hirano, K; Hotta, Y; Kajiwara, Y; Kobayashi, Y; Sugimoto, Y; Tagawa, N; Yamada, J; Yamada, S | 1 |
Ikonomidis, I; Kremastinos, DT; Lekakis, J; Moutsatsou, P; Nikolaou, M; Papoutsi, Z; Parissis, J | 1 |
Amitani, H; Asakawa, A; Fujimiya, M; Fujitsuka, N; Hayashi, M; Inui, A; Kojima, S; Sameshima, M | 1 |
Hasegawa, R; Ikeda, K; Karasawa, J; Tamura, K; Yamamoto, H; Yamamoto, T; Yasumoto, S | 1 |
Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T | 1 |
Bloch, MH; Coric, V; Dombrowski, P; Goodman, WK; Kelmendi, B; Krystal, JH; Landeros-Weisenberger, A; Leckman, JF; Nudel, J; Pittenger, C; Wegner, R | 1 |
Charles, D; Fava, M; Papakostas, GI | 1 |
Dormuth, CR; Lee, JC; Mehta, J; Miller, M; Patrick, AR; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
Dormuth, C; Lee, JC; Mehta, J; Miller, M; Patrick, AR; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P | 1 |
Mochcovitch, MD; Nardi, AE | 1 |
Antonioli, L; Blandizzi, C; Colucci, R; Corona, T; Fornai, M; Mantarro, S; Montagnani, S; Pergola, A; Ruggiero, E; Scollo, C; Testi, A; Tuccori, M | 1 |
Hazell, P; Silove, N; Wheeler, DM; Williams, K | 1 |
Dobzhenko, MN; Shchepotin, IB; Zotov, AS | 1 |
Cao, XH; Li, K; Lin, M; Shen, PC; Wang, HT; Wang, R; Xu, DF; Zheng, J | 1 |
Fallon, BA; Pavlicova, M; Schweitzer, PJ; Zafar, U | 1 |
Dasgupta, K; Labos, C; Nedjar, H; Rahme, E; Turecki, G | 1 |
Cavanna, AE; Rickards, H; Worrall, R | 1 |
Barata C, C; Campos, B; Piña, B | 1 |
Mandrioli, R; Mercolini, L; Raggi, MA; Saracino, MA | 1 |
Andrade, C | 2 |
Hidaka, H; Mitsutsuka, Y; Oyama, T; Serpone, N; Takamura, T; Tsukamoto, T | 1 |
Gorman, DA; Lam, D; Patten, S; Pringsheim, T | 1 |
Barata, C; Campos, B; Escalon, L; Garcia-Reyero, N; Habib, T; Piña, B; Rivetti, C; Tauler, R; Tsakovski, S | 1 |
Brignell, A; Hazell, P; Randall, M; Silove, N; Williams, K | 1 |
Hermann, M; Molden, E; Waade, RB | 1 |
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N | 1 |
Banzi, R; Cusi, C; Moja, L; Randazzo, C; Sterzi, R; Tedesco, D | 1 |
Halling-Sørensen, B; Hansen, CH; Jacobsen, NW; Nellemann, C; Styrishave, B | 1 |
Delgermurun, D; Ito, S; Ohta, T; Otsuguro, K; Yamaguchi, S | 1 |
Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL | 1 |
Ask, KS; Bardakci, T; Gjelstad, A; Halvorsen, TG; Parmer, MP; Pedersen-Bjergaard, S; Øiestad, EL | 1 |
Casavant, MJ; Chounthirath, T; Russell, JL; Spiller, HA | 1 |
Daws, LC; Koek, W; Sandoval, TL | 1 |
Drobniewska, A; Nałęcz-Jawecki, G; Sikorska, K; Wawryniuk, M | 1 |
Assimon, MM; Brookhart, MA; Flythe, JE | 1 |
Arnold, PD; Bousman, C; Greenslade, A; Maruf, AA | 1 |
Liao, XM; Si, TM; Su, YA; Wang, Y; Yu, X | 1 |
Hui, A | 1 |
Chen, L; Feng, X; Huang, C; Shen, X; Wang, J; Xu, T | 1 |
Aghaeepour, N; Maric, I; Oskotsky, B; Oskotsky, T; Sirota, M; Stevenson, DK; Tang, A; Wong, RJ | 1 |
Hoertel, N | 1 |
Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA | 1 |
Bálint, BL; Hermán, L; Mahdi, M; Réthelyi, JM | 1 |
Al-Khatib, SM; Assimon, MM; Brookhart, MA; Flythe, JE; Gaynes, BN; Pun, PH; Winkelmayer, WC | 1 |
da Rosa, TF; Foletto, VS; Hörner, R; Serafin, MB | 1 |
Azoulay, L; Cao, TXD; Fergusson, E; Filliter, C; Montastruc, F; Rej, S; Renoux, C; Yu, OHY | 1 |
Bayati, R; Ghaffari Jolfayi, A; Nakhaee, H; Rahmanian, M; Rakhshanderou, S; Zangiabadian, M | 1 |
Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F | 1 |
Izumi, Y; Lenze, EJ; Mennerick, SJ; Reiersen, AM; Zorumski, CF | 1 |
Chen, C; Li, Q; Liu, YN; Xie, S; Xu, RA; Zhan, R | 1 |
Keidan, L; Pick, CG; Schreiber, S | 1 |
Blakely, RD; Groshan, K; Richelson, E; Tatsumi, M | 1 |
79 review(s) available for fluoxetine and fluvoxamine
Article | Year |
---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
Topics: Allosteric Regulation; Clinical Trials as Topic; Humans; Ligands; Nervous System Diseases; Piperidines; Receptors, sigma; Sigma-1 Receptor; Small Molecule Libraries | 2020 |
The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder.
Topics: Brain; Clomipramine; Dopamine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Serotonin; Tourette Syndrome | 1992 |
Serotonergic probes in obsessive compulsive disorder.
Topics: Brain; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Receptors, Serotonin; Serotonin | 1992 |
[New horizons in drug therapy of depression].
Topics: Antidepressive Agents; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Time Factors | 1992 |
Pharmacokinetics of the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Serotonin Antagonists; Sertraline | 1992 |
The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Topics: 1-Naphthylamine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; In Vitro Techniques; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Serotonin Antagonists; Sertraline | 1992 |
Pharmacotherapy of obsessive compulsive disorder.
Topics: 1-Naphthylamine; Antidepressive Agents; Clomipramine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Neurotransmitter Uptake Inhibitors; Obsessive-Compulsive Disorder; Paroxetine; Piperidines; Serotonin; Sertraline | 1992 |
The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy.
Topics: Antidepressive Agents; Depressive Disorder; Desipramine; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Imipramine; Mianserin; Suicide | 1991 |
Obsessive-compulsive disorder.
Topics: Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder | 1991 |
5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour.
Topics: Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Mianserin; Paroxetine; Piperidines; Serotonin Antagonists; Suicide; Suicide Prevention | 1991 |
Fluoxetine and fluvoxamine.
Topics: Antidepressive Agents; Fluoxetine; Fluvoxamine; Humans; Oximes | 1991 |
New pharmacologic approaches to obsessive compulsive disorder.
Topics: Behavior Therapy; Clinical Trials as Topic; Clomipramine; Combined Modality Therapy; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Obsessive-Compulsive Disorder; Oximes | 1990 |
A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Topics: 1-Naphthylamine; Adult; Ambulatory Care; Clinical Trials as Topic; Clomipramine; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Meta-Analysis as Topic; Obsessive-Compulsive Disorder; Oximes; Placebos; Psychiatric Status Rating Scales; Serotonin; Serotonin Antagonists; Sertraline | 1990 |
Biochemical pharmacology of the serotonin system.
Topics: Alanine; Brain; Citalopram; Clomipramine; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Neurons; Oximes; p-Chloroamphetamine; Paroxetine; Piperidines; Propylamines; Receptors, Serotonin; Reserpine; Serotonin; Serotonin Antagonists; Synapses; Tetrabenazine; Zimeldine | 1986 |
Therapeutic effects of serotonin uptake inhibitors in depression.
Topics: 5-Hydroxytryptophan; Alanine; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Imipramine; Oximes; Paroxetine; Piperidines; Propylamines; Serotonin; Serotonin Antagonists; Trazodone; Zimeldine | 1986 |
Clinical experience with serotonin reuptake inhibiting antidepressants.
Topics: Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Oximes; Propylamines; Serotonin Antagonists; Zimeldine | 1987 |
Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine.
Topics: Animals; Antidepressive Agents; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Oximes; Serotonin; Serotonin Antagonists; Trazodone | 1987 |
Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Topics: 1-Naphthylamine; Animals; Citalopram; Cytochrome P-450 Enzyme System; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Stereoisomerism | 1995 |
Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Topics: 1-Naphthylamine; Alcoholism; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
Topics: 1-Naphthylamine; Adolescent; Adult; Clomipramine; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Multicenter Studies as Topic; Obsessive-Compulsive Disorder; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1995 |
Management of treatment-refractory obsessive compulsive disorder patients.
Topics: Antipsychotic Agents; Behavior Therapy; Clomipramine; Clonazepam; Combined Modality Therapy; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Electroconvulsive Therapy; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Obsessive-Compulsive Disorder; Treatment Outcome | 1994 |
The pharmacogenetics of the selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 Enzyme System; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Pharmacogenetics; Selective Serotonin Reuptake Inhibitors | 1993 |
The pharmacotherapy of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Buspirone; Clomipramine; Desipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; Sertraline | 1993 |
[New antidepressive agents].
Topics: 1-Naphthylamine; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzamides; Child; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Moclobemide; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1995 |
Use of serotonin selective reuptake inhibitors in geriatric depression.
Topics: 1-Naphthylamine; Age Factors; Aged; Controlled Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Are pharmacokinetic drug interactions with the SSRIs an issue?
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Liver; Selective Serotonin Reuptake Inhibitors | 1996 |
Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Female; Fluoxetine; Fluvoxamine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Paroxetine; Product Surveillance, Postmarketing; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I.
Topics: Cytochrome P-450 CYP1A1; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Isoenzymes; Microsomes, Liver; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Buspirone; Child; Clomipramine; Clonazepam; Costs and Cost Analysis; Dopamine Antagonists; Drug Interactions; Drug Tolerance; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Lithium; Obsessive-Compulsive Disorder; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Tryptophan | 1996 |
Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
Topics: 1-Naphthylamine; Animals; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Fluoxetine; Fluvoxamine; Humans; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Movement disorders associated with the serotonin selective reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Age Factors; Aged; Akathisia, Drug-Induced; Depressive Disorder; Dyskinesia, Drug-Induced; Dystonia; Female; Fluoxetine; Fluvoxamine; Humans; Male; MEDLINE; Middle Aged; Parkinson Disease, Secondary; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; United States | 1996 |
The role of SSRIs in panic disorder.
Topics: 1-Naphthylamine; Citalopram; Clinical Trials as Topic; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients.
Topics: 1-Naphthylamine; Chromatography; Citalopram; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Female; Fluoxetine; Fluvoxamine; Headache; Humans; Infant; Infant, Newborn; Male; MEDLINE; Mental Disorders; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensation Disorders; Sertraline; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 1997 |
SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 1997 |
Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Topics: 1-Naphthylamine; Antidepressive Agents; Cyclohexanols; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1997 |
Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Clinical Trials as Topic; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Meta-Analysis as Topic; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1997 |
The use of newer antidepressants for panic disorder.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 1997 |
Pharmacokinetic interactions of antidepressants.
Topics: Antidepressive Agents; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Mixed Function Oxygenases; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1998 |
SSRI safety in overdose.
Topics: Adult; Child; Citalopram; Drug Overdose; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Poison Control Centers; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 1998 |
Depression and dementia: comorbidities, identification, and treatment.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Benzamides; Citalopram; Clomipramine; Cognition Disorders; Comorbidity; Dementia; Depression; Female; Fluoxetine; Fluvoxamine; Humans; Imipramine; Male; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Nortriptyline; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Current concepts in the treatment of panic disorder.
Topics: Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Meta-Analysis as Topic; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
Pharmacokinetics of selective serotonin reuptake inhibitors.
Topics: Citalopram; Clinical Trials as Topic; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2000 |
On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
Topics: Clomipramine; Double-Blind Method; Expert Testimony; Fluoxetine; Fluvoxamine; Guidelines as Topic; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2000 |
Pharmacoeconomic studies of antidepressants: focus on venlafaxine.
Topics: Antidepressive Agents, Second-Generation; Buspirone; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclohexanols; Depressive Disorder; Drug Tolerance; Fluoxetine; Fluvoxamine; Humans; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2000 |
Psychopharmacologic treatment of adolescent depression.
Topics: Adolescent; Child; Cyclohexanols; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2001 |
The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Behavior, Animal; Citalopram; Clinical Trials as Topic; Comorbidity; Drinking Behavior; Drug Evaluation, Preclinical; Fluoxetine; Fluvoxamine; Humans; Mice; Rats; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Serotonin agents in the treatment of acquired brain injury.
Topics: Brain Injuries; Citalopram; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Injury Severity Score; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2002 |
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2002 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior Therapy; Child; Citalopram; Clomipramine; Depression; Diagnosis, Differential; Eczema; Family Practice; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychotherapy; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline; Surveys and Questionnaires; Time Factors; Trichotillomania | 2003 |
Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Topics: Autistic Disorder; Citalopram; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chemotherapy, Adjuvant; Fluoxetine; Fluvoxamine; Humans; Schizophrenia; Schizophrenic Psychology; Selective Serotonin Reuptake Inhibitors | 2004 |
Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Child Development Disorders, Pervasive; Cross-Over Studies; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Randomized Controlled Trials as Topic; Reproducibility of Results; Risperidone; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2005 |
Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Fluoxetine; Fluvoxamine; Humans; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2005 |
[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Case-Control Studies; Child, Preschool; Citalopram; Confidence Intervals; Depressive Disorder; Family Practice; Female; Fluoxetine; Fluvoxamine; History, Medieval; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Placebos; Psychotherapy; Randomized Controlled Trials as Topic; Risk; Safety; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Suicide; Suicide, Attempted | 2006 |
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2008 |
Use of medication in children with psychiatric disorders.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; Drug Prescriptions; Drug Utilization; Fluoxetine; Fluvoxamine; Health Policy; Humans; Melatonin; Mental Disorders; Methylphenidate; Needs Assessment; Patient Selection; Practice Guidelines as Topic; Practice Patterns, Physicians'; Propylamines; Psychotropic Drugs; Risperidone; Sertraline; United Kingdom | 2007 |
Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
Topics: Adult; Citalopram; Female; Fluoxetine; Fluvoxamine; Humans; Odds Ratio; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2008 |
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult | 2010 |
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
Topics: Citalopram; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Placebo Effect; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Topics: Abnormalities, Drug-Induced; Cardiovascular Abnormalities; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Humans; Maternal-Fetal Exchange; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Sertraline; Teratogens | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2010 |
[Selective serotonin reuptake inhibitors and mammary pathologies].
Topics: Antidepressive Agents; Breast Neoplasms; Citalopram; Clinical Trials as Topic; Female; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Topics: Benzofurans; Citalopram; Depressive Disorder; Drug Monitoring; Fluoxetine; Fluvoxamine; Humans; Indoles; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Vilazodone Hydrochloride | 2012 |
Drug interactions in the treatment of depression in patients with ischemic heart disease.
Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C19; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Early Diagnosis; Fluoxetine; Fluvoxamine; Gastrointestinal Hemorrhage; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Selective Serotonin Reuptake Inhibitors; Ticlopidine | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Child Development Disorders, Pervasive; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2013 |
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Tension-Type Headache; Venlafaxine Hydrochloride | 2015 |
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2016 |
Antidepressant pharmacogenetics in children and young adults: A systematic review.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mental Disorders; Nortriptyline; Paroxetine; Pharmacogenetics; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tryptophan Hydroxylase; Venlafaxine Hydrochloride; Young Adult | 2019 |
Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.
Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Desvenlafaxine Succinate; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Psychometrics; Sertraline; Treatment Outcome | 2020 |
Recent sample pretreatment methods for determination of selective serotonin reuptake inhibitors (SSRIs) in biological samples.
Topics: Citalopram; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2021 |
Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.
Topics: Antidepressive Agents; COVID-19 Drug Treatment; Fluoxetine; Fluvoxamine; Humans; Pandemics; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors | 2022 |
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use.
Topics: Antidepressive Agents; Antiviral Agents; COVID-19 Drug Treatment; Fluoxetine; Fluvoxamine; Humans; Receptors, Serotonin; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors; Serotonin | 2022 |
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.
Topics: Antidepressive Agents; COVID-19 Drug Treatment; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Topics: COVID-19; Fluoxetine; Fluvoxamine; Humans; Selective Serotonin Reuptake Inhibitors | 2023 |
38 trial(s) available for fluoxetine and fluvoxamine
Article | Year |
---|---|
A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Topics: 1-Naphthylamine; Adult; Ambulatory Care; Clinical Trials as Topic; Clomipramine; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Meta-Analysis as Topic; Obsessive-Compulsive Disorder; Oximes; Placebos; Psychiatric Status Rating Scales; Serotonin; Serotonin Antagonists; Sertraline | 1990 |
Clinical experience with serotonin reuptake inhibiting antidepressants.
Topics: Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Oximes; Propylamines; Serotonin Antagonists; Zimeldine | 1987 |
Are SSRI antidepressants a clinically homogeneous class of compounds?
Topics: Adult; Aged; Bipolar Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors | 1994 |
Carbamazepine coadministration with fluoxetine or fluvoxamine.
Topics: Adult; Carbamazepine; Depression; Drug Interactions; Drug Therapy, Combination; Epilepsy, Complex Partial; Epilepsy, Tonic-Clonic; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged | 1993 |
An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
Topics: Adult; Ambulatory Care; Buspirone; Depressive Disorder; Desipramine; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors | 1993 |
Response to an open trial of a second SSRI in major depression.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.
Topics: Adult; Amitriptyline; Antipsychotic Agents; Clomipramine; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Pharmacogenetics; Phenotype | 1995 |
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Chromatography, High Pressure Liquid; Citalopram; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sparteine | 1996 |
A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Nausea; Selective Serotonin Reuptake Inhibitors | 1996 |
Serotonergic drugs in trichotillomania: treatment results in 12 patients.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Recurrence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Trichotillomania | 1996 |
Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
Topics: Adult; Clomipramine; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; Time Factors | 1996 |
Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer.
Topics: Alcoholism; Anti-Anxiety Agents; Buspirone; Dose-Response Relationship, Drug; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Patient Compliance; Riboflavin; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Ultraviolet Rays | 1996 |
Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Middle Aged; Selective Serotonin Reuptake Inhibitors | 1997 |
19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Brain; Brain Chemistry; Drug Administration Schedule; Fluorine; Fluoxetine; Fluvoxamine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Obsessive-Compulsive Disorder; Tissue Distribution; Treatment Outcome | 1997 |
Personality disorder scores improve with effective pharmacotherapy of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Ergolines; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Disorders; Personality Inventory; Serotonin Antagonists | 1997 |
Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adrenergic Uptake Inhibitors; Adult; Clomipramine; Desipramine; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1997 |
SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 1997 |
Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Ejaculation; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Reaction Time; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Depressive Disorder; Double-Blind Method; Echocardiography; Electrocardiography; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors | 1998 |
Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors.
Topics: Adult; Analysis of Variance; Depressive Disorder; Double-Blind Method; Female; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Male; Prolactin; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Time Factors | 1999 |
A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Topics: Adult; Ambulatory Care; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Pindolol; Placebos; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 1999 |
CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
Topics: Adult; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Reference Values; Sertraline | 1999 |
Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: three cases.
Topics: Adult; Chronic Disease; Drug Resistance; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Trichotillomania | 1999 |
Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
Topics: Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Administration Schedule; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Implosive Therapy; Obsessive-Compulsive Disorder; Pilot Projects; Psychiatric Status Rating Scales; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder.
Topics: Adult; Antidepressive Agents; Cohort Studies; Combat Disorders; Disasters; Female; Fluoxetine; Fluvoxamine; Humans; Lamotrigine; Male; Middle Aged; Personality Inventory; Piperazines; Psychometrics; Rape; Reproducibility of Results; Stress Disorders, Post-Traumatic; Triazines; Triazoles | 1999 |
On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
Topics: Clomipramine; Double-Blind Method; Expert Testimony; Fluoxetine; Fluvoxamine; Guidelines as Topic; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2000 |
Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.
Topics: Fluoxetine; Fluvoxamine; Humans; Methadone; Narcotics; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Stereoisomerism; Substance-Related Disorders | 1997 |
Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Libido; Male; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Surveys and Questionnaires; Time Factors | 2000 |
An open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa.
Topics: Adolescent; Adult; Bulimia; Comorbidity; Female; Fluoxetine; Fluvoxamine; Humans; Multi-Institutional Systems; Personality Inventory; Phototherapy; Placebos; Psychiatric Status Rating Scales; Retrospective Studies; Seasonal Affective Disorder; Severity of Illness Index; Treatment Outcome | 2001 |
Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
Topics: Adolescent; Adult; Age of Onset; Ambulatory Care; Behavior Therapy; Clomipramine; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Probability; Prognosis; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Topics: Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Fluoxetine; Fluvoxamine; Genotype; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study.
Topics: Adolescent; Anxiety Disorders; Child; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Pediatrics; Psychopharmacology; Regression Analysis | 2002 |
Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors | 2003 |
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Humans; Ketoconazole; Male; Midazolam; Piperazines; Triazoles | 2003 |
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Male; Obesity; Obsessive-Compulsive Disorder; Paroxetine; Patient Compliance; Prospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2004 |
Phenytoin as an augmentation for SSRI failures: a small controlled study.
Topics: Adult; Aged; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Phenytoin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules.
Topics: Adult; Aged; Aorta; Cell Adhesion; Cell Survival; Chronic Disease; Citalopram; Depression; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fluoxetine; Fluvoxamine; Heart Failure; Humans; Intercellular Adhesion Molecule-1; Middle Aged; Monocytes; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Tumor Necrosis Factor-alpha; U937 Cells; Vascular Cell Adhesion Molecule-1 | 2010 |
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2021 |
182 other study(ies) available for fluoxetine and fluvoxamine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Inhibition of P-glycoprotein by newer antidepressants.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
Topics: Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Ligands; Models, Molecular; Molecular Structure; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2021 |
Effects of inhibitors of neuronal uptake of 5-HT on sympathetic cardiovascular regulation.
Topics: Analysis of Variance; Animals; Blood Platelets; Blood Pressure; Citalopram; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Heart Rate; Norepinephrine; Rabbits; Serotonin; Sympathetic Nervous System | 1992 |
Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias.
Topics: Adolescent; Adult; Behavior, Addictive; Clomipramine; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Obsessive-Compulsive Disorder; Paraphilic Disorders; Psychiatric Status Rating Scales; Retrospective Studies; Serotonin | 1992 |
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Topics: 1-Naphthylamine; Antidepressive Agents, Tricyclic; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sparteine | 1992 |
Treatment outcome of obsessive compulsive disorder with comorbid social phobia.
Topics: Adult; Clomipramine; Comorbidity; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Phenelzine; Phobic Disorders; Probability; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1992 |
Metabolic interaction between tricyclic antidepressant and fluvoxamine and fluoxetine, a pharmacogenetic approach.
Topics: Adult; Antidepressive Agents, Tricyclic; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Pharmacogenetics | 1992 |
Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal results.
Topics: Biotransformation; Chromatography, High Pressure Liquid; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans | 1992 |
Sodium valproate augmentation of fluoxetine or fluvoxamine effects.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Valproic Acid | 1992 |
Fluoxetine and fluvoxamine in PTSD.
Topics: Adult; Drug Evaluation; Fluoxetine; Fluvoxamine; Humans; Male; Serotonin; Stress Disorders, Post-Traumatic; Veterans | 1992 |
Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine.
Topics: Alleles; Amitriptyline; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Debrisoquin; Depression; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Half-Life; Humans; Middle Aged; Nortriptyline; Phenotype; Spectrophotometry, Ultraviolet | 1991 |
Fluoxetine, fluvoxamine and extrapyramidal tract disorders.
Topics: Adult; Basal Ganglia Diseases; Female; Fluoxetine; Fluvoxamine; Humans; Mental Disorders; Middle Aged; Movement; Oximes; Serotonin Antagonists | 1991 |
Are effective antiobsessional drugs interchangeable?
Topics: Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Research Design; Serotonin Antagonists | 1991 |
Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
Topics: Adult; Clomipramine; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Oximes; Serotonin Antagonists | 1990 |
Treatment of depersonalization with serotonin reuptake blockers.
Topics: Adolescent; Adult; Clomipramine; Depersonalization; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Oximes; Panic; Serotonin Antagonists | 1990 |
Apathy and indifference in patients on fluvoxamine and fluoxetine.
Topics: Adult; Agoraphobia; Antidepressive Agents; Anxiety Disorders; Arousal; Depressive Disorder; Dose-Response Relationship, Drug; Fatigue; Female; Fluoxetine; Fluvoxamine; Humans; Impulsive Behavior; Male; Middle Aged; Motivation; Oximes; Panic; Serotonin Antagonists | 1990 |
Obsessive-compulsive disorder.
Topics: Adult; Behavior Therapy; Clomipramine; Diagnosis, Differential; Female; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Oximes; Physicians, Family; Serotonin Antagonists | 1989 |
Obsessive compulsive disorder.
Topics: Behavior Therapy; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Oximes | 1989 |
5-HT reuptake inhibitors in healthy human subjects.
Topics: Fluoxetine; Fluvoxamine; Humans; Neuropsychological Tests; Oximes; Propylamines; Psychometrics; Serotonin; Serotonin Antagonists | 1986 |
Interactions of 5HT reuptake inhibitors and ethanol in tests of exploration and anxiety.
Topics: Animals; Anxiety; Citalopram; Desipramine; Drug Interactions; Ethanol; Exploratory Behavior; Fluoxetine; Fluvoxamine; Mice; Mice, Inbred Strains; Motor Activity; Oximes; Serotonin Antagonists | 1988 |
Behavioral interactions of fluoxetine and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration.
Topics: Animals; Anxiety; Citalopram; Desipramine; Ethanol; Exploratory Behavior; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Oximes; Serotonin Antagonists | 1988 |
The antidepressant agents desipramine, fluoxetine, fluvoxamine and norzimelidine inhibit uptake of [3H]noradrenaline and [3H]5-hydroxytryptamine in slices of human and rat cortical brain tissue.
Topics: Absorption; Animals; Antidepressive Agents; Cerebral Cortex; Desipramine; Fluoxetine; Fluvoxamine; Humans; In Vitro Techniques; Male; Norepinephrine; Oximes; Rats; Serotonin; Zimeldine | 1983 |
Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors.
Topics: Animals; Antidepressive Agents, Tricyclic; Brain; Brompheniramine; Cattle; Fluoxetine; Fluvoxamine; Male; Neurons; Oximes; Propylamines; Rats; Rats, Inbred Strains; Receptors, Histamine; Receptors, Neurotransmitter; Serotonin; Zimeldine | 1983 |
Effects of chronic treatment with antidepressants on aggressiveness induced by clonidine in mice.
Topics: Aggression; Animals; Antidepressive Agents; Citalopram; Clonidine; Drug Interactions; Fluoxetine; Flupenthixol; Fluvoxamine; Humans; Male; Mice; Oximes; Pizotyline; Propylamines; Stereoisomerism | 1982 |
The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain.
Topics: 1-Naphthylamine; Animals; Appetite Depressants; Brain Chemistry; Eating; Fluoxetine; Fluvoxamine; Hydroxyindoleacetic Acid; Indoles; Male; Paroxetine; Rats; Rats, Inbred Strains; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 1993 |
Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.
Topics: 1-Naphthylamine; 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Aggression; Analysis of Variance; Animals; Behavior, Animal; Brain; Citalopram; Dose-Response Relationship, Drug; Fenclonine; Fluoxetine; Fluvoxamine; Male; Mice; Paroxetine; Penbutolol; Piperidines; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Sertraline; Synaptosomes | 1994 |
In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine.
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Fluoxetine; Fluvoxamine; Imipramine; Male; Microdialysis; Norepinephrine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin | 1994 |
Are SSRI antidepressants clinically homogeneous?
Topics: Depressive Disorder; Fluoxetine; Fluvoxamine; Humans | 1994 |
Chlorimipramine and nortriptyline but not fluoxetine and fluvoxamine inhibit human polymorphonuclear cell chemotaxis in vitro.
Topics: Antidepressive Agents; Chemotaxis, Leukocyte; Clomipramine; Fluoxetine; Fluvoxamine; Humans; In Vitro Techniques; Neutrophils; Nortriptyline | 1994 |
Prescription-event monitoring of 10,401 patients treated with fluvoxamine.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Depressive Disorder; Drug Monitoring; Drug Prescriptions; Drug Therapy, Combination; England; Family Practice; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Pregnancy; Product Surveillance, Postmarketing; Sex Factors | 1994 |
Fluvoxamine in obsessive-compulsive nonresponders to clomipramine or fluoxetine.
Topics: Adult; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Severity of Illness Index | 1994 |
Pharmacologic management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Antidepressive Agents; Anxiety Disorders; Clomipramine; Depression; Dopamine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Synaptic Transmission; Trazodone | 1994 |
Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Panic Disorder; Suicide | 1993 |
Antisocial ideation and activities precipitated by the administration of SSRIs.
Topics: Adult; Antisocial Personality Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Impulsive Behavior; Male; Risk Factors; Selective Serotonin Reuptake Inhibitors | 1993 |
Drug-induced mania.
Topics: Bipolar Disorder; Clomipramine; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Risk Factors | 1993 |
Differential effects of fluoxetine on isoprenaline-stimulated water intake in ethanol-treated rats: a role for beta-adrenoceptors.
Topics: Analysis of Variance; Animals; Desipramine; Drinking; Drug Interactions; Ethanol; Fluoxetine; Fluvoxamine; Injections, Intraperitoneal; Isoproterenol; Male; Propranolol; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Zimeldine | 1993 |
[Risk of hemorrhage with the use of fluoxetine (Prozac) or fluvoxamine (Fevarin)].
Topics: Adult; Female; Fluoxetine; Fluvoxamine; Hematoma; Hemorrhage; Humans | 1993 |
Blood-letting in bulimia nervosa.
Topics: Adult; Bloodletting; Bulimia; Child of Impaired Parents; Combined Modality Therapy; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Personality Development; Phenelzine; Phototherapy; Psychotherapy; Psychotherapy, Group; Students, Medical | 1993 |
[Risk of hemorrhage with administration of fluoxetine (Prozac) or fluvoxamine (Fevarin)].
Topics: Ascorbic Acid; Ecchymosis; Female; Fluoxetine; Fluvoxamine; Humans | 1993 |
Pharmacological properties of 403U76, a new chemical class of 5-hydroxytryptamine- and noradrenaline-reuptake inhibitor.
Topics: 5-Hydroxytryptophan; Adrenergic Uptake Inhibitors; Animals; Animals, Newborn; Benzyl Alcohols; Binding, Competitive; Dogs; Electrophysiology; Fluoxetine; Fluvoxamine; Hemodynamics; Imipramine; Male; Mice; Neurons; Norepinephrine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Species Specificity; Synaptic Transmission; Tetrabenazine; Vocalization, Animal | 1995 |
Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors.
Topics: Adult; Clomipramine; Cyproheptadine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological | 1995 |
In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function. Microdialysis studies.
Topics: Adrenergic Uptake Inhibitors; Animals; Carrier Proteins; Cerebral Cortex; Citalopram; Clonidine; Desipramine; Fluoxetine; Fluvoxamine; Imipramine; Male; Membrane Glycoproteins; Membrane Transport Proteins; Microdialysis; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Raphe Nuclei; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Symporters | 1996 |
Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry.
Topics: Fluoxetine; Fluvoxamine; Gas Chromatography-Mass Spectrometry; Humans; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism | 1996 |
Fluoxetine addition to methadone in addicts: pharmacokinetic aspects.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Humans; Male; Methadone; Mood Disorders; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 1996 |
Predicting value of tryptophan/large neutral amino acids ratio on selective serotonin reuptake inhibitors.
Topics: Amino Acids; Antidepressive Agents; Biomarkers; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Predictive Value of Tests; Selective Serotonin Reuptake Inhibitors; Tryptophan | 1996 |
Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects.
Topics: 1-Naphthylamine; Aged; Anorexia; Antidepressive Agents; Depressive Disorder; Diarrhea; Fluoxetine; Fluvoxamine; Humans; Meta-Analysis as Topic; Nausea; Paroxetine; Patient Dropouts; Selective Serotonin Reuptake Inhibitors; Sertraline; Single-Blind Method | 1996 |
[Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Belgium; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Netherlands; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Effects of antidepressants on the cytochrome P450 system.
Topics: 1-Naphthylamine; Antidepressive Agents; Cytochrome P-450 Enzyme System; Fluoxetine; Fluvoxamine; Humans; Medical Records; Paroxetine; Research Design; Sertraline | 1996 |
A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Product Surveillance, Postmarketing; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 1996 |
A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study.
Topics: 1-Naphthylamine; Adolescent; Adult; Aged; Fluoxetine; Fluvoxamine; Humans; Libido; Male; Middle Aged; Paraphilic Disorders; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Rats; Rats, Wistar; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sertraline; Vocalization, Animal | 1997 |
Behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat.
Topics: 1-Naphthylamine; Animals; Behavior, Animal; Chlorpromazine; Citalopram; Fluoxetine; Fluvoxamine; Guanidines; Haloperidol; Male; Microinjections; Motor Activity; Paroxetine; Piperidines; Posture; Rats; Rats, Sprague-Dawley; Receptors, sigma; Red Nucleus; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |
Emergence of kleptomania during treatment for depression with serotonin selective reuptake inhibitors.
Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Disruptive, Impulse Control, and Conduct Disorders; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors | 1997 |
Effects of fluoxetine hydrochloride and fluvoxamine maleate on different preparations of isolated guinea pig and rat organ tissues.
Topics: Acetylcholine; Animals; Antidepressive Agents; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Guinea Pigs; In Vitro Techniques; Male; Muscle, Smooth; Norepinephrine; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Receptors, Histamine; Receptors, Muscarinic; Selective Serotonin Reuptake Inhibitors | 1997 |
Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test.
Topics: Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Desipramine; Drug Interactions; Fluoxetine; Fluvoxamine; Imipramine; Ketanserin; Male; Maprotiline; Mice; Ondansetron; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Ritanserin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Swimming | 1997 |
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Dysthymic Disorder; Epilepsy; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Panic Disorder; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1997 |
Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Fluoxetine; Fluvoxamine; Frozen Sections; Humans; Hydroxylation; Imipramine; In Vitro Techniques; Lethal Dose 50; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Venlafaxine Hydrochloride | 1997 |
[A comparative clinical evaluation of the antidepressive activity of fluoxetine and fluvoxamine].
Topics: Adolescent; Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Evaluation; Female; Fluoxetine; Fluvoxamine; Humans; Male; Maprotiline; Middle Aged; Time Factors | 1997 |
ACTH 4-9 analogue facilitates the antiimmobility effect of antidepressants and dopamine agonists in swimming rats.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Dopamine Agonists; Exploratory Behavior; Fear; Fluoxetine; Fluvoxamine; Monoamine Oxidase Inhibitors; Motor Activity; Peptide Fragments; Piribedil; Quinpirole; Rats; Rats, Wistar; Selegiline; Swimming | 1997 |
Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
Topics: Comorbidity; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors | 1997 |
Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine.
Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Pregnanolone; Psychometrics; Selective Serotonin Reuptake Inhibitors; Stereoisomerism | 1998 |
Pinch-induced catalepsy in mice: a useful model to investigate antidepressant or anxiolytic drugs.
Topics: Amitriptyline; Animals; Anti-Anxiety Agents; Antidepressive Agents; Catalepsy; Female; Fluoxetine; Fluvoxamine; Imipramine; Learning; Male; Mice; Models, Psychological; Motor Activity; Ondansetron; Physical Stimulation; Reaction Time; Serotonin Antagonists; Sex Characteristics; Stereotyped Behavior | 1998 |
In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine.
Topics: Buprenorphine; Cytochrome P-450 Enzyme System; Fluoxetine; Fluvoxamine; Humans; In Vitro Techniques; Linear Models; Methadone; Microsomes, Liver; Narcotic Antagonists; Narcotics; Selective Serotonin Reuptake Inhibitors | 1998 |
[Choice of therapeutic tactics in treatment of endogenous depression by means of statusmetric expert system].
Topics: 1-Naphthylamine; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Treatment Outcome | 1997 |
Selective serotonin reuptake inhibitors may enhance responses to noxious stimulation.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Fluvoxamine; Heart Rate; Hot Temperature; Male; Pain; Pain Measurement; Rats; Rats, Wistar; Reaction Time; Selective Serotonin Reuptake Inhibitors | 1998 |
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exercise Test; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 1998 |
Stimulus properties of fluvoxamine in a conditioned taste aversion procedure.
Topics: Animals; Avoidance Learning; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Male; Mice; Mice, Inbred ICR; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Taste | 1998 |
Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
Topics: Adolescent; Adult; Child; Citalopram; Cytochrome P-450 Enzyme System; Drug Prescriptions; Fluoxetine; Fluvoxamine; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Divided attention in major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Attention; Decision Making; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Reaction Time | 1998 |
Milnacipran: new preparation. Tricyclics remain first-line antidepressants.
Topics: Amitriptyline; Antidepressive Agents; Clinical Trials as Topic; Clomipramine; Cyclopropanes; Drug Evaluation; Europe; Fluoxetine; Fluvoxamine; Humans; Imipramine; Meta-Analysis as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; United States | 1998 |
Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Disease Models, Animal; Eating; Ethanol; Female; Fluoxetine; Fluvoxamine; Food Preferences; Male; Paroxetine; Rats; Rats, Mutant Strains; Selective Serotonin Reuptake Inhibitors | 1999 |
Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Dendritic Cells; Fluoxetine; Fluvoxamine; Golgi Apparatus; Hippocampus; Male; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Receptors, Serotonin; Restraint, Physical; Stress, Physiological; Thiazepines | 1999 |
The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies.
Topics: Animals; Antipsychotic Agents; Brain; Chromatography, High Pressure Liquid; Fluoxetine; Fluvoxamine; Male; Microsomes, Liver; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Sertraline; Thioridazine | 1999 |
Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Clomipramine; Comorbidity; Controlled Clinical Trials as Topic; Factor Analysis, Statistical; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Personality Inventory; Placebo Effect; Placebos; Probability; Psychiatric Status Rating Scales; Regression Analysis; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tic Disorders; Treatment Outcome | 1999 |
Excretion of paroxetine into breast milk.
Topics: Adult; Breast Feeding; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Humans; Lactation; Milk, Human; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Triglycerides | 1999 |
Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms.
Topics: Animals; Blood Glucose; Enzyme Inhibitors; Fenclonine; Fluoxetine; Fluvoxamine; Hyperglycemia; Insulin; Male; Maprotiline; Mice; Selective Serotonin Reuptake Inhibitors; Time Factors | 1999 |
Determination of fluoxetine, fluvoxamine, and clomipramine in pharmaceutical formulations by capillary gas chromatography.
Topics: Chromatography, Gas; Clomipramine; Drug Stability; Fluoxetine; Fluvoxamine; Pharmaceutical Preparations; Quality Control; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Solutions; Temperature | 2000 |
Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Fluorometry; Fluoxetine; Fluvoxamine; Humans; Linear Models; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline | 2000 |
Application of chrome azurol S for the extractive spectrophotometric determination of fluoxetine and fluvoxamine.
Topics: Fluoxetine; Fluvoxamine; Hydroxybenzoates; Pharmaceutical Preparations; Selective Serotonin Reuptake Inhibitors; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet | 2000 |
Investigation and analytical application of the reactions of eriochrome cyanine R with fluvoxamine and fluoxetine.
Topics: Benzenesulfonates; Coloring Agents; Fluoxetine; Fluvoxamine; Selective Serotonin Reuptake Inhibitors; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet | 2000 |
Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.
Topics: Adult; Aged; Brain; Depressive Disorder, Major; Female; Fluorine Radioisotopes; Fluoxetine; Fluvoxamine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors | 2000 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Determination of four selective serotonin reuptake inhibitors by capillary isotachophoresis.
Topics: Citalopram; Electrophoresis, Capillary; Fluoxetine; Fluvoxamine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2000 |
Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine proliferation in hippocampus.
Topics: Adrenergic Uptake Inhibitors; Animals; Cell Count; Dendrites; Desipramine; Fluoxetine; Fluvoxamine; Hippocampus; Male; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2000 |
Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.
Topics: Adult; Antidepressive Agents; Cross-Sectional Studies; Drug Costs; Fluoxetine; Fluvoxamine; Forecasting; Humans; Insurance Claim Reporting; Insurance, Pharmaceutical Services; Middle Aged; Models, Theoretical; Ontario; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
Comparison of noradrenergic and serotonergic antidepressants in reducing immobility time in the tail suspension test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Desipramine; Fluoxetine; Fluvoxamine; Male; Models, Animal; Nortriptyline; Rats; Rats, Inbred Strains; Selective Serotonin Reuptake Inhibitors; Synaptic Transmission; Tail | 2001 |
The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.
Topics: Animals; Brain; Dopamine Antagonists; Drug Interactions; Fluoxetine; Fluvoxamine; Infusions, Parenteral; Male; Perazine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine.
Topics: Adolescent; Feeding and Eating Disorders; Fluoxetine; Fluvoxamine; Humans; Male; Prader-Willi Syndrome; Selective Serotonin Reuptake Inhibitors | 2001 |
[The transfer of selective serotonin reuptake inhibitors to human milk].
Topics: Antidepressive Agents; Breast Feeding; Citalopram; Depression, Postpartum; Female; Fluoxetine; Fluvoxamine; Humans; Infant; Infant, Newborn; Milk, Human; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
Serotonin reuptake inhibitor antidepressants and pregnancy: many unanswered questions.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Second-Generation; Child; Child, Preschool; Clinical Trials as Topic; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Infant; Infant, Newborn; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Topics: Animals; Binding, Competitive; Body Temperature; Brain; Cerebral Cortex; Fluoxetine; Fluvoxamine; Indoles; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Degeneration; Nerve Endings; Neuroprotective Agents; Paroxetine; Rats; Rectum; Serotonin; Serotonin Agents; Time Factors; Tritium | 2001 |
Physical exercise: an adjunctive treatment for panic disorder?
Topics: Adult; Combined Modality Therapy; Exercise; Female; Fluoxetine; Fluvoxamine; Humans; Middle Aged; Panic Disorder; Psychotherapy; Treatment Outcome | 2001 |
Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Autistic Disorder; Brain; Brain Chemistry; Child; Child Development Disorders, Pervasive; Depressive Disorder; Dose-Response Relationship, Drug; Fluorine; Fluoxetine; Fluvoxamine; Half-Life; Humans; Magnetic Resonance Spectroscopy; Middle Aged; Obsessive-Compulsive Disorder; Panic Disorder; Selective Serotonin Reuptake Inhibitors | 2002 |
Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Behavior, Animal; Binding, Competitive; Brain Chemistry; Conditioning, Psychological; Cyclopropanes; Dose-Response Relationship, Drug; Fear; Fluoxetine; Fluvoxamine; Imipramine; Male; Maprotiline; Microdialysis; Milnacipran; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Prefrontal Cortex; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cell Surface; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming; Synaptosomes; Time Factors | 2002 |
Photoisomerization of fluvoxamine generates an isomer that has reduced activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Brain; Cell Division; Cells, Cultured; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Drug Stability; Fluoxetine; Fluvoxamine; In Vitro Techniques; Male; Photochemistry; Rats; Rats, Sprague-Dawley; Serotonin; Stereoisomerism; Synaptosomes; Ultraviolet Rays | 2002 |
Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Animals; Brain; Clomipramine; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Ergolines; Fluoxetine; Fluvoxamine; Male; Maprotiline; Mice; Motor Activity; Neurons; Norepinephrine; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Synaptic Transmission | 2002 |
Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
Topics: Citalopram; Clinical Pharmacy Information Systems; Cost Control; Cost Savings; Drug Administration Schedule; Drug Costs; Drug Utilization; Fluoxetine; Fluvoxamine; Hospital Costs; Hospitals, Veterans; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2003 |
Drug-related hyperprolactinemia.
Topics: Antidepressive Agents; Antipsychotic Agents; Female; Flunarizine; Fluoxetine; Fluvoxamine; Humans; Hyperprolactinemia; Indoramin; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sulpiride | 2003 |
Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens.
Topics: Animals; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Fluvoxamine; Injections, Intraperitoneal; Male; Microdialysis; Motor Activity; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2003 |
Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus.
Topics: Animals; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Male; Selective Serotonin Reuptake Inhibitors; Shrews; Vomiting | 2003 |
Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac).
Topics: Animals; Brain; Dose-Response Relationship, Drug; Ethanol; Female; Fluoxetine; Fluvoxamine; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Heart; Mice; Potassium Channels; Potassium Channels, Inwardly Rectifying; RNA, Messenger; Xenopus laevis; Zimeldine | 2003 |
Study and analytical application of ion-pair formation in the system fluoxetine-pyrocatechol violet and fluvoxamine-pyrocatechol violet.
Topics: Albumins; Antidepressive Agents, Second-Generation; Benzenesulfonates; Coloring Agents; Fluoxetine; Fluvoxamine; Indicators and Reagents; Magnetic Resonance Spectroscopy; Spectrophotometry, Infrared; Spectrophotometry, Ultraviolet; Tablets | 2003 |
Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Blood Glucose; Body Weight; Desipramine; Diabetes Mellitus, Experimental; Diazepam; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Hindlimb Suspension; Male; Mice; Mice, Inbred ICR; Motor Activity; Selective Serotonin Reuptake Inhibitors | 2003 |
An interaction between carbamazepine and fluvoxamine.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Carbamazepine; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Humans; Middle Aged | 1993 |
Serotonin uptake and metabolism by cultured guinea pig airway smooth muscle cells.
Topics: Animals; Cells, Cultured; Clomipramine; Fluoxetine; Fluvoxamine; Guinea Pigs; Muscle, Smooth; Selective Serotonin Reuptake Inhibitors; Serotonin; Trachea | 2004 |
Different effects of selective serotonin reuptake inhibitors on a patient suffering from panic disorder.
Topics: Adult; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Hypnotics and Sedatives; Male; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bone Marrow; Brain; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Female; Fluorine Radioisotopes; Fluoxetine; Fluvoxamine; Humans; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Middle Aged; Protons; Selective Serotonin Reuptake Inhibitors; Time Factors | 2004 |
Neonatal complications after intrauterine exposure to SSRI antidepressants.
Topics: Antidepressive Agents; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; France; Humans; Infant, Newborn; Neonatal Abstinence Syndrome; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Risk; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Costs; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Acute and chronic toxicity of five selective serotonin reuptake inhibitors in Ceriodaphnia dubia.
Topics: Animals; Citalopram; Cladocera; Ecosystem; Female; Fluoxetine; Fluvoxamine; Lethal Dose 50; Male; No-Observed-Adverse-Effect Level; Paroxetine; Reproduction; Selective Serotonin Reuptake Inhibitors; Sertraline; Toxicity Tests, Acute; Toxicity Tests, Chronic; Water Pollutants, Chemical | 2004 |
In vivo identification and characterization of binding sites for selective serotonin reuptake inhibitors in mouse brain.
Topics: Analysis of Variance; Animals; Area Under Curve; Binding Sites; Brain; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Male; Mice; Mice, Inbred ICR; Paroxetine; Radioligand Assay; Receptors, Serotonin; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Sertraline; Tritium | 2004 |
A sensitive HPLC method for the determination of fluoxetine and norfluoxetine in human plasma with fluorescence detection.
Topics: Administration, Oral; Area Under Curve; Benzofurans; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Monitoring; Fluoxetine; Fluvoxamine; Half-Life; Hexanes; Humans; Kinetics; Reference Standards; Sensitivity and Specificity | 2005 |
Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
Topics: Animals; Behavior, Animal; Binding Sites; Brain; Fluoxetine; Fluvoxamine; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred ICR; Motor Activity; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2005 |
Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
Topics: Cognition Disorders; Corpus Striatum; Fluoxetine; Fluvoxamine; Frontal Lobe; Humans; Nerve Net; Neuropsychological Tests; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
Serotonin and its antidepressant-sensitive transport in mouse cumulus-oocyte complexes and early embryos.
Topics: Animals; Antidepressive Agents, Second-Generation; Blastocyst; Cell Communication; Cricetinae; Female; Fluoxetine; Fluvoxamine; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Nerve Tissue Proteins; Oocytes; Pregnancy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tryptophan Hydroxylase | 2005 |
Depression in general clinical practice.
Topics: Age Factors; Aged; Antidepressive Agents; Citalopram; Depression; Family Practice; Female; Fluoxetine; Fluvoxamine; Humans; Male; Risk Factors; Treatment Outcome | 2004 |
(+)-Norfenfluramine-induced arterial contraction is not dependent on endogenous 5-hydroxytryptamine or 5-hydroxytryptamine transporter.
Topics: Animals; Aorta; Fluoxetine; Fluvoxamine; Ketanserin; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Norfenfluramine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tryptophan Hydroxylase; Vasoconstriction | 2005 |
Rapid screening of selective serotonin re-uptake inhibitors in urine samples using solid-phase microextraction gas chromatography-mass spectrometry.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Gas Chromatography-Mass Spectrometry; Humans; Mianserin; Mirtazapine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sertraline; Solid Phase Microextraction; Venlafaxine Hydrochloride | 2005 |
Exposure assessment and microcosm fate of selected selective serotonin reuptake inhibitors.
Topics: Environmental Exposure; European Union; Fluoxetine; Fluvoxamine; Forecasting; Humans; Models, Theoretical; Selective Serotonin Reuptake Inhibitors; Sertraline; United States; Water Pollutants, Chemical | 2005 |
Approach to novel functional foods for stress control 4. Regulation of serotonin transporter by food factors.
Topics: Animals; Anthracenes; Biflavonoids; Bridged Bicyclo Compounds; Carrier Proteins; Cell Differentiation; Cell Line; Cell Lineage; Cells, Cultured; Fluoxetine; Fluvoxamine; Food; Hypericum; Ligands; Macrophages; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Osteoclasts; Perylene; Phloroglucinol; Plant Extracts; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Recombinant Proteins; Serotonin; Stress, Physiological; Terpenes; Time Factors | 2005 |
From selective to highly selective SSRIs: a comparison of the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram.
Topics: Analgesics; Animals; Citalopram; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Male; Mice; Mice, Inbred ICR; Pain Measurement; Selective Serotonin Reuptake Inhibitors | 2006 |
The spermicidal and antitrichomonas activities of SSRI antidepressants.
Topics: Animals; Antidepressive Agents; Antitrichomonal Agents; Drug Evaluation, Preclinical; Fluoxetine; Fluvoxamine; Humans; In Vitro Techniques; Male; Molecular Structure; Selective Serotonin Reuptake Inhibitors; Sertraline; Spermatocidal Agents; Spermatozoa; Structure-Activity Relationship; Trichomonas vaginalis | 2006 |
Cognitive behavioral therapy versus psychosurgery for refractory obsessive-compulsive disorder.
Topics: Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Gyrus Cinguli; Humans; Middle Aged; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care; Psychosurgery | 2006 |
Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromsø, Norway.
Topics: Calibration; Chemical Fractionation; Chromatography, High Pressure Liquid; Citalopram; Fluoxetine; Fluvoxamine; Norway; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline; Sewage; Water Pollutants, Chemical | 2006 |
Toxicity and hazard of selective serotonin reuptake inhibitor antidepressants fluoxetine, fluvoxamine, and sertraline to algae.
Topics: Biomass; Chlorella vulgaris; Dose-Response Relationship, Drug; Eukaryota; Fluoxetine; Fluvoxamine; Phytoplankton; Risk Assessment; Scenedesmus; Selective Serotonin Reuptake Inhibitors; Sertraline; Species Specificity; Structure-Activity Relationship; Time Factors; Water Pollutants, Chemical | 2007 |
Decision-making functioning as a predictor of treatment outcome in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Mass Index; Cognition Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Decision Making; Demography; Female; Fluoxetine; Fluvoxamine; Gambling; Humans; Interview, Psychological; Neuropsychological Tests; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2006 |
Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat.
Topics: Animals; Antidepressive Agents, Second-Generation; Arachidonic Acid; Brain; Cytosol; Fluoxetine; Fluvoxamine; Frontal Lobe; Injections, Intraperitoneal; Male; Phospholipases A; Phospholipids; Rats; Rats, Inbred F344; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Selective Serotonin Reuptake Inhibitors; Up-Regulation | 2007 |
Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction.
Topics: Algorithms; Amines; Animals; Biological Transport; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Dextromethorphan; Fluoxetine; Fluvoxamine; Hepatocytes; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Imipramine; In Vitro Techniques; Kinetics; Male; Models, Biological; Propranolol; Quinine; Rats; Rats, Sprague-Dawley | 2007 |
Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
Topics: Animals; Catalysis; Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Inhibitors; Fluconazole; Fluoxetine; Fluvoxamine; Hepatocytes; Ketoconazole; Kinetics; Male; Miconazole; Microsomes, Liver; Midazolam; Phenytoin; Quinine; Rats; Rats, Sprague-Dawley; Tolbutamide | 2007 |
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Topics: Adult; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Demography; Drug Resistance; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy.
Topics: Antidepressive Agents; Coitus; Data Interpretation, Statistical; Ejaculation; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Mirtazapine; Models, Biological; Piperazines; Reaction Time; Research Design; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline; Sexual Dysfunction, Physiological; Treatment Outcome; Triazoles | 2008 |
Quality assessment of fluoxetine and fluvoxamine pharmaceutical formulations purchased in different countries or via the Internet by 19F and 2D DOSY 1H NMR.
Topics: beta-Cyclodextrins; Chemistry, Pharmaceutical; Fluoxetine; Fluvoxamine; Humans; Internet; Magnetic Resonance Spectroscopy | 2008 |
Mouse strain differences in immobility and sensitivity to fluvoxamine and desipramine in the forced swimming test: analysis of serotonin and noradrenaline transporter binding.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depression; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Inbred ICR; Motor Activity; Norepinephrine Plasma Membrane Transport Proteins; Serotonin Plasma Membrane Transport Proteins; Species Specificity; Swimming | 2008 |
Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin.
Topics: Animals; Drugs, Chinese Herbal; Eating; Fenfluramine; Fluoxetine; Fluvoxamine; Gastrointestinal Motility; Ghrelin; Growth Hormone; Injections, Intraventricular; Male; Oligopeptides; Paroxetine; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Receptors, Ghrelin; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists | 2009 |
Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Topics: Animals; Dopamine; Fluoxetine; Fluvoxamine; Haloperidol; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Wistar; Reserpine; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Vesicular Monoamine Transport Proteins | 2009 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger | 2009 |
Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
Topics: Adult; Clomipramine; Connecticut; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Personality Inventory; Prognosis; Psychometrics; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2010 |
Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Cohort Studies; Cross-Sectional Studies; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide; Suicide Prevention; Suicide, Attempted | 2010 |
Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Topics: Adult; Aged; Antidepressive Agents; British Columbia; Cause of Death; Citalopram; Cohort Studies; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Hospitalization; Humans; Male; Middle Aged; Paroxetine; Proportional Hazards Models; Risk; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide, Attempted | 2010 |
Neonatal exposure to fluoxetine and fluvoxamine alteres spine density in mouse hippocampal CA1 pyramidal neurons.
Topics: Animals; Animals, Newborn; Behavior, Animal; Brain; Dendrites; Exploratory Behavior; Fluoxetine; Fluvoxamine; Male; Mice; Mice, Transgenic; Motor Activity; Pyramidal Cells; Selective Serotonin Reuptake Inhibitors | 2011 |
Long-term follow-up of hypochondriasis after selective serotonin reuptake inhibitor treatment.
Topics: Adolescent; Adult; Aged; Child Abuse; Clinical Trials as Topic; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Hypochondriasis; Male; Middle Aged; Personality Disorders; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Canada; Citalopram; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Heart Failure; Hemorrhage; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Neoplasms; Paroxetine; Peptic Ulcer; Platelet Aggregation Inhibitors; Renal Insufficiency; Retrospective Studies; Risk; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Ticlopidine | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Depression; Europe; Fluoxetine; Fluvoxamine; Health Care Surveys; Humans; Methylphenidate; Obsessive-Compulsive Disorder; Physicians; Piperazines; Propylamines; Psychiatry; Quinolones; Risperidone; Sertraline; Sulpiride; Tourette Syndrome | 2012 |
Mechanisms of action of selective serotonin reuptake inhibitors in Daphnia magna.
Topics: Animals; Body Size; Carbohydrate Metabolism; Cyproheptadine; Daphnia; Female; Fluoxetine; Fluvoxamine; Humans; Life Cycle Stages; Lipid Metabolism; Oxygen Consumption; Proteins; Reproduction; Selective Serotonin Reuptake Inhibitors; Survival Analysis; Water Pollutants, Chemical | 2012 |
Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
Topics: Adult; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Clomipramine; Clozapine; Comorbidity; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2012 |
Photoassisted defluorination of fluorinated substrates and pharmaceuticals by a wide bandgap metal oxide in aqueous media.
Topics: Fluorides; Fluoxetine; Fluvoxamine; Gallium; Halogenation; Hydrogen-Ion Concentration; Kinetics; Oxidation-Reduction; Photolysis; Toluene; Ultraviolet Rays; Water | 2013 |
The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents; Canada; Child; Child, Preschool; Citalopram; Databases, Factual; Fluoxetine; Fluvoxamine; Humans; Infant; Mental Disorders; Paroxetine; Practice Patterns, Physicians'; Selective Serotonin Reuptake Inhibitors; Sertraline | 2013 |
Identification of metabolic pathways in Daphnia magna explaining hormetic effects of selective serotonin reuptake inhibitors and 4-nonylphenol using transcriptomic and phenotypic responses.
Topics: Animals; Daphnia; Female; Fluoxetine; Fluvoxamine; Hormesis; Oligonucleotide Array Sequence Analysis; Phenols; Phenotype; Selective Serotonin Reuptake Inhibitors; Transcriptome | 2013 |
Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Child; Citalopram; Databases, Factual; Drug Monitoring; Drug Utilization; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Norway; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Young Adult | 2015 |
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Moclobemide; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2015 |
Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay.
Topics: Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Citalopram; Estradiol; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Progesterone; Selective Serotonin Reuptake Inhibitors; Sertraline; Testosterone | 2015 |
Endogenous 5-HT outflow from chicken aorta by 5-HT uptake inhibitors and amphetamine derivatives.
Topics: Animals; Aorta, Thoracic; Chickens; Clomipramine; Fluoxetine; Fluvoxamine; In Vitro Techniques; Male; Methamphetamine; p-Chloroamphetamine; Selective Serotonin Reuptake Inhibitors; Serotonin | 2016 |
Parallel artificial liquid membrane extraction as an efficient tool for removal of phospholipids from human plasma.
Topics: Chromatography, Liquid; Fluoxetine; Fluvoxamine; Humans; Lysophosphatidylcholines; Membranes, Artificial; Pharmaceutical Preparations; Phosphatidylcholines; Phospholipids; Plasma; Quetiapine Fumarate; Sphingomyelins; Tandem Mass Spectrometry; Technology, Pharmaceutical | 2016 |
Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications.
Topics: Child; Child, Preschool; Citalopram; Coma; Dose-Response Relationship, Drug; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Hospitalization; Humans; Infant; Male; Paroxetine; Poison Control Centers; Retrospective Studies; Seizures; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Vilazodone Hydrochloride | 2017 |
Effects of the antidepressants desipramine and fluvoxamine on latency to immobility and duration of immobility in the forced swim test in adult male C57BL/6J mice.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Depression; Desipramine; Disease Models, Animal; Fluoxetine; Fluvoxamine; Immobilization; Male; Mice; Mice, Inbred C57BL; Motor Activity; Swimming | 2018 |
Influence of photolabile pharmaceuticals on the photodegradation and toxicity of fluoxetine and fluvoxamine.
Topics: Ciliophora; Fluoxetine; Fluvoxamine; Humic Substances; Photolysis; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2018 |
Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Conduction System Disease; Citalopram; Death, Sudden, Cardiac; Depression; Electrocardiography; Female; Fluoxetine; Fluvoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peroxidase; Registries; Renal Dialysis; Retrospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; United States | 2019 |
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Least-Squares Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2020 |
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; COVID-19; Cytokines; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Prescription Drugs; Retrospective Studies; Risk; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; United States | 2021 |
Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
Topics: Antidepressive Agents; COVID-19 Drug Treatment; Fluoxetine; Fluvoxamine; Humans; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors | 2021 |
The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.
Topics: Case-Control Studies; Citalopram; Cohort Studies; Death, Sudden, Cardiac; Dialysis Solutions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Potassium; Renal Dialysis; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2022 |
Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths.
Topics: Adolescent; Antipsychotic Agents; Citalopram; Diabetes Mellitus, Type 2; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2022 |
SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids.
Topics: Animals; Anti-Inflammatory Agents; COVID-19; Drug Inverse Agonism; Fluoxetine; Fluvoxamine; Hippocampus; Lipopolysaccharides; Neurosteroids; Rats; Selective Serotonin Reuptake Inhibitors | 2023 |
Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS/MS.
Topics: Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Fluconazole; Fluoxetine; Fluvoxamine; Humans; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2023 |
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Mianserin; Mice; Mirtazapine; Moclobemide; Naloxone; Reboxetine; Trazodone; Venlafaxine Hydrochloride | 2023 |
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
Topics: Antidepressive Agents; Brain; Carrier Proteins; Cell Line; Dopamine Plasma Membrane Transport Proteins; Humans; In Vitro Techniques; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Radioligand Assay; Serotonin Plasma Membrane Transport Proteins; Symporters; Synaptosomes | 1997 |